HTG Molecular Diagnostics Cultura da Companhia

Dr. Debra A. Gordon, also known as Deb, Ph.D., J.D., has been the Chief Legal Counsel and Vice President of HTG Molecular Diagnostics, Inc. since June 20, 2011. Prior to joining HTG, Dr. Gordon was General Counsel and Head, Patent Legal at Ventana, a medical diagnostics company and a member of the Roche Group and the global headquarters for RTD, from October 2008 to June 2011. Dr. Gordon was promoted to leadership of the Ventana legal function after serving at Ventana from February 2007 as a patent attorney supporting the assay development functions. For nearly ten years preceding Dr. Gordon's in-house legal experiences, Dr. Gordon practiced as a business transactional attorney at the law firms Lewis and Roca LLP (now, Lewis Roca Rothgerber LLP) and Perkins Coie LLP and as an intellectual property attorney at the law firm Klarquist Sparkman LLP. Prior to law school, Dr. Gordon completed post-doctoral fellowships at Brandeis University and the University of Arizona. Dr. Gordon is an author on 13 peer-reviewed scientific publications and an inventor on two patent filings and one issued U.S. patent. Dr. Gordon received a B.S. in Biology and Chemistry and a M.S. in Chemistry from Western Washington University, a Ph.D. in Physiology from the University of Arizona, College of Medicine and a J.D. with honors from the University of Arizona, James E. Rogers College of Law.

Mr. Shaun D. McMeans has been the Chief Financial Officer and Vice President of Finance & Administration at HTG Molecular Diagnostics, Inc. since February 2012. Mr. McMeans serves as Treasurer at HTG Molecular Diagnostics, Inc. Mr. McMeans has over 20 years experience in manufacturing and distribution businesses, specializing in financial management, accounting and corporate development. He joined HTG Molecular in February, 2012 and leads its finance and administration groups. Immediately prior to joining HTG Molecular, he served as the Chief Financial Officer and Vice President of Finance for Securaplane Technologies in Tucson and division of Meggitt PLC, an aerospace, defense and energy conglomerate, from May 2011 to February 2012. He was a financial consultant from February 2008 to April 2011, working both in an individual capacity and as a partner for Tatum LLC. He also worked for over five years at LXU Healthcare, Inc., a manufacturer and distributor of specialty surgical equipment, as Controller and then Chief Financial and Operating Officer. Prior to February 2008, he extensive experience includes positions as Chief Financial Officer of The Long Companies and interim Chief Financial Officer with Fluoresco and Inter-Fab. He served as Chief Financial Officer and Chief Operating Officer of Integra Luxtec, Inc. from January 2002 to July 29, 2005 and served as its Principal Accounting Officer, Treasurer and clerk until July 29, 2005. Mr. McMeans served as Chief Operating Officer and Chief Financial Officer of Luxtec Corporation. He also served as a Senior Vice President of Corporate Development of Primesource Healthcare Inc. He served as its Vice President of Operations and Corporate Controller. Prior to joining PrimeSource in April 2000, Mr. McMeans worked in roles of increasing responsibility, including Director of Finance, for Burnham Holdings, Inc., formerly Burnham Corporation, a manufacturer and distributor of residential and commercial hydronic heating equipment. He began his career in public accounting with the former Peat, Marwick, Mitchell and Company. He served as a Director of Integra Luxtec, Inc. from September 1, 2003 to July 29, 2005. He served as a Director of PrimeSource Healthcare, Inc. and Luxtec Corporation since September 1, 2003. Mr. McMeans earned a Bachelor of Science degree in accounting from The Pennsylvania State University and is a Certified Public Accountant.

Mr. John L. Lubniewski has been the Vice President and Chief Business Officer of HTG Molecular Diagnostics, Inc. since April 2011. Mr. Lubniewski is responsible for leading the sales, marketing and product development teams for HTG's three strategic business areas: molecular testing capabilities for translational medicine, pharmaceutical clinical development and pathology laboratory diagnostics. He has more than 20 years of management experience in the life science sector. He joined HTG from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of Roche Tissue Diagnostics, or RTD, where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche in March 2008. From August 2010 to April 2011, he was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010, he served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years at Corning, Inc., a manufacturing company, in a variety of divisional, sector and corporate sales and marketing roles. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University.

Dr. Patrick C. Roche, also known as Pat, Ph.D., has been the Senior Vice President of Research and Product Development at HTG Molecular Diagnostics, Inc. since April 2014. Dr. Roche served as Senior Vice President for IVD Assay Development at HTG Molecular Diagnostics, Inc. since April 09, 2014. Dr. Roche joined HTG from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of RTD, where he worked for 12 years and held a number of positions of increasing responsibility, including Vice President, Head Biomarker Strategy, Translational Diagnostics, from August 2009 to April 2014 and Vice President, Assay Development and Clinical Studies, from March 2007 to July 2009. In these roles, Dr. Roche was responsible for interfacing with pharmaceutical partners in their development of targeted cancer therapeutics and facilitating the transition of biomarkers into companion diagnostics and for leading reagent product development and launching over 30 in vitro diagnostic products, including the FDA-approved c-kit and HER2 tests. Prior to working at Ventana, Dr. Roche was at the Mayo Clinic Rochester, a medical research group, where he served as Director of the Immunohistochemistry Laboratory and as Associate Professor of Laboratory Medicine and Pathology. Dr. Roche has co-authored more than 125 peer-reviewed publications and is an inventor on a number of patent filings and two issued U.S. patents. Dr. Roche received a B.S. in Biological Sciences from the University of Southern California and a Ph.D. in Experimental Pathology from the University of Southern California, School of Medicine.

Patrick Roche serves as the Sr Vice President of HTG Molecular Diagnostics. Patrick started at HTG Molecular Diagnostics in April of 2014. Patrick currently resides in Tucson, Arizona Area.

Maureen Cronin serves as the CSO/SVP of HTG Molecular Diagnostics. Maureen started at HTG Molecular Diagnostics in November of 2018. Maureen currently resides in the San Francisco Bay Area.